Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy

NCT00063752 is registered in ClinicalTrials.gov with Peptimmune as lead sponsor.

NCT NCT00063752
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00063752 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy
Lead sponsor
Peptimmune
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2003
Completion date
March 31, 2005
Enrollment
15
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

pemphigus vulgaris